Related Experiment Video
Updated: Oct 4, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer
Salomé Adam1, Silvia Emma Rossi1, Nathalie Moatti1
1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Abstract:
BRCA1/2-mutated cancer cells adapt to the genome instability caused by their deficiency in homologous recombination (HR). Identification of these adaptive mechanisms may provide therapeutic strategies to target tumors caused by the loss of these genes. In the present study, we report genome-scale CRISPR-Cas9 synthetic lethality screens in isogenic pairs of BRCA1- and BRCA2-deficient cells and identify CIP2A as an essential gene in BRCA1- and BRCA2-mutated cells. CIP2A is cytoplasmic in interphase but, in mitosis, accumulates at DNA lesions as part of a complex with TOPBP1, a multifunctional genome stability factor. Unlike PARP inhibition, CIP2A deficiency does not cause accumulation of replication-associated DNA lesions that require HR for their repair. In BRCA-deficient cells, the CIP2A-TOPBP1 complex prevents lethal mis-segregation of acentric chromosomes that arises from impaired DNA synthesis. Finally, physical disruption of the CIP2A-TOPBP1 complex is highly deleterious in BRCA-deficient tumors, indicating that CIP2A represents an attractive synthetic lethal therapeutic target for BRCA1- and BRCA2-mutated cancers.
Insights
Cancer cells with BRCA1/2 mutations rely on CIP2A for survival. Targeting the CIP2A-TOPBP1 complex offers a new therapeutic strategy for BRCA-mutated cancers.
Area of Science:
- Genetics
- Molecular Biology
- Cancer Research
Background:
- BRCA1/2-mutated cancers exhibit genome instability due to homologous recombination (HR) deficiency.
- Understanding adaptive mechanisms in these cells is crucial for developing targeted therapies.
Purpose of the Study:
- To identify essential genes and adaptive mechanisms in BRCA1/2-deficient cancer cells.
- To evaluate CIP2A as a potential synthetic lethal target for BRCA-mutated tumors.
Main Methods:
- Genome-scale CRISPR-Cas9 synthetic lethality screens were performed in isogenic BRCA1- and BRCA2-deficient cell lines.
- CIP2A's role and its complex with TOPBP1 were investigated in mitosis and at DNA lesions.
Main Results:
- CIP2A was identified as essential in BRCA1- and BRCA2-mutated cells.
- The CIP2A-TOPBP1 complex, localized at DNA lesions during mitosis, prevents lethal chromosome mis-segregation in BRCA-deficient cells.
- CIP2A deficiency did not induce replication-associated DNA lesions requiring HR.
Conclusions:
- CIP2A is a critical factor for the survival of BRCA-deficient cancer cells.
- Disrupting the CIP2A-TOPBP1 complex is highly detrimental to BRCA-mutated tumors.
- CIP2A represents a promising synthetic lethal therapeutic target for BRCA1/2-mutated cancers.
Related Concept Videos
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
DNA Damage can Stall the Cell Cycle
The Intrinsic Apoptotic Pathway
Negative Regulator Molecules
Separation of Sister Chromatids
At the onset of anaphase, separase, a proteolytic enzyme, is...
Anaphase Promoting Complex

